MON-805 Gaps In Osteoporosis Management And Risk Stratification In A Predominantly Hispanic Population

Abstract Disclosure: R.L. Moraes Dantas: None. J. Sekar: None. G. Renganathan: None. Introduction: Osteoporosis is a common disease, and your screening bone measurement testing is well known. Despite the availability of dual- energy absorptiometry x-ray (DXA), osteoporosis frequently remains untreated. Objectives: To describe the osteoporosis risk factors, assess the use of the fracture risk assessment tool (FRAX) and the osteoporosis treatment gap among women with osteopenia or osteoporosis in the community served by our clinic. Methods: The present study is a retrospective chart review of 387 women diagnosed with osteopenia/osteoporosis over the course of one year (January 1, 2023 - December 31, 2023). Inclusion criteria were medical charts with the ICD-10 codes for osteoporosis and osteopenia (M81.0, M81.8, M80, M85.80). Charts of women under 50 years of age and men were excluded. Data collected includes demographic information (self-reported race/ethnicity and age at the time of diagnosis), previous medical history (previous fractures, smoking history, alcohol use, steroid use for more than 3 months, body mass index, diagnosis of rheumatoid arthritis, osteoarthritis, chronic kidney disease, and liver disease), and quality of care indicators (documentation of FRAX score, use of osteoporosis medications in patients with osteoporosis and high-risk osteopenia, and frequency of DXA scans). Patient records were reviewed from January 1, 2019 to December 31, 2023. Results: A total of 462 patients were identified based on predetermined ICD-10 codes. After excluding 75 medical charts, the study sample consisted of 387 women: 225 (58.1%) with osteoporosis and 162 (41.9%) with osteopenia. 321 patients (82.9%) were Hispanic or Latino. Risk factors included glucocorticoid use for more than three months in 36 patients (9.3%), smoking in 25 (6.5%), and diagnosis of rheumatoid arthritis in 31 (8%). FRAX scores were calculated for 61 patients (37.6%) with osteopenia. Osteoporosis medication was prescribed to 151 patients (67.1%) with osteoporosis and to 42 patients (72.41%) with high-risk osteopenia. Among our study population, only 212 (54.8%) were taking vitamin D, and 163 (42.1%) were taking calcium supplements. Conclusion: Our study identified a care gap in management of osteoporosis/osteopenia and in the assessment of fracture risk among our Hispanic community. Most of our patients were not assessed by 10-year fracture risk with FRAX score, and nearly half were not on vitamin D and calcium. Presentation: Monday, July 14, 2025